JNJ-42041935 is described as a potent, competitive, and selective inhibitor of prolyl hydroxylase (PHD), demonstrating inhibition of PHD1, PHD2, and PHD3 with specific pKi values. It has been investigated for its efficacy in reversing inflammation-induced anemia in rat models and for increasing reticulocytes, hemoglobin, and hematocrit in vivo.
- Potent inhibition of specific enzymes.
- Competitive and selective mode of action.
- Effective in reversing anemia in preclinical models.
- Increases red blood cell precursors, hemoglobin, and hematocrit in animal studies.